Demcizumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | DLL4 |
| Identifiers | |
| CAS Number | 1243262-17-0 |
| ATC code | none |
| IUPHAR/BPS | 8451 |
| Chemical data | |
| Formula | C6444H10004N1700O2028S52 |
| Molecular mass | 145.3 kg/mol |
Demcizumab /dɛmˈsɪzᵿmæb/ is a humanized monoclonal antibody designed for the treatment of cancer.[1]
As of 2015, the drug is being developed by OncoMed Pharmaceuticals in non-small-cell lung cancer as well as pancreatic cancer, in collaboration with Celgene.
Mechanism of action
Demcizumab blocks Delta-like ligand 4 (DLL4), a ligand of Notch receptors. Notch signaling has been implicated as a key signaling pathway in cancer stem cells. By treating patients with a combination of Demcizumab and a cytotoxic chemotherapy, it is hoped that a more durable anti-tumor response can be achieved than with chemotherapy alone.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.(registration required)
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Pages with login required references or sources
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibody stubs
- Monoclonal antibodies
